The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

A twice-a-year injectable drug has been shown to be 100% effective in preventing the spread of HIV, according to the first data from a clinical trial. If approved, the drug offers another preventive ...